Merrimack Pharmaceuticals Story Overview

MACK -- USA Stock  

USD 4.21  0.05  1.17%

Macroaxis does not monitor all media channels or aggregates social signals for Merrimack Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on Merrimack Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Merrimack Pharmaceuticals. Please see also Merrimack Pharmaceuticals Hype Analysis, Merrimack Pharmaceuticals Correlation and Merrimack Pharmaceuticals Performance.
Acquisition by John Mendelsohn of 7500 shares of Merrimack Pharmaceuticals subject to Rule 16b-3
Filed transaction by Merrimack Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3

Merrimack Pharmaceuticals Inc insider trading alert for grant of stock option (right to buy) by John Mendelsohn, the corporate stakeholder, on December 7, 2017. This event was filed by Merrimack Pharmaceuticals with SEC on 2017-09-15. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This media report from MacroaxisInsider distributed on December 7, 2017 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 0.95% . The trading delta at closing time when the story was published against the current closing price is 59.44% .

Similar stores for Merrimack Pharmaceuticals

Northern Trust Corp Cuts Stake in Merrimack Pharmaceuticals Inc - Baseball Daily Newsnews
Northern Trust Corp Cuts Stake in Merrimack Pharmaceuticals Inc Baseball Daily NewsNorthern Trust Corp cut its position in Merrimack Pharmaceuticals Inc by 69.0 percent during the second quarter, according to its most recent Form ...
few days ago at http://finexaminer.com 
Shapiro Capital Management Stake in Patterson Companies Has Lowered by 63.47 Million Pnm Res Stock Value Rose ...
news
Shapiro Capital Management Stake in Patterson Companies Has Lowered by 63.47 Million Pnm Res Stock Value Rose While Gamco Investors Et Al Trimmed Its Stake The FinExaminerShapiro Capital Management Llc decreased its stake in Patterson Companies Inc. by 0.1 percent based on its latest 2018Q2 regulatory filing with the SEC.
over two weeks ago at http://pressoracle.com 
BlackRock Inc. Has 1.24 Million Holdings in Merrimack Pharmaceuticals Inc
news
PressOracleFull coverage
over three weeks ago at http://www.baseballdailydigest.com 
Bank of New York Mellon Corp Has 211000 Stake in Merrimack Pharmaceuticals Inc
news
Baseball Daily NewsFull coverage
over three weeks ago at http://www.law360.com 
Ex-Merrimack Analyst Gets 6 Months For Insider Trading
news
Law360Full coverage
over a month ago at http://thewellesleysnews.com 
Analyst Research and Ratings STRATA Skin Sciences, Inc. , Merrimack Pharmaceuticals, Inc.
news
Analyst JournalFull coverage
over a month ago at http://nasdaqclick.com 
Merrimack Pharmaceuticals, Inc. Recent Trading Updates
nasdaq News
Nasdaq Click Full coverage
over a month ago at http://www.streetinsider.com 
Merrimack Pharma Reports Termination of Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small ...
Street Insider News
StreetInsider.comFull coverage
over two months ago at http://stockmarketfloor.com 
Merrimack Pharmaceuticals, Inc. move of -3.38 percent on Tuesday and 3-months average volume stands at 65.17 ....
news
Stock Market Floor Full coverage
over two months ago at http://www.thewellesleysnews.com 
Analyst Research and Recommendations Clear Channel Outdoor Holdings, Inc. , Merrimack Pharmaceuticals ...
news
Analyst JournalFull coverage
over three months ago at http://pressoracle.com 
Childrens Place Inc Shares Bought by Tower Research Capital LLC TRC
news
PressOracleFull coverage
over three months ago at http://simplywall.st 
Merrimack Pharmaceuticals Inc Is Breakeven Near
news
Simply Wall StInvestors Taking Another Look at Merrimack Pharmaceuticals, Inc. After Recent Market Moves The Coin GuildFull coverage
over six months ago at http://utahherald.com 
Merrimack Pharmaceuticals, Inc. Reaches 8.57 After 3.00 percent Up Move Global Med Technologies Has 1.23 ...
news
UtahHerald.comFull coverage

Current Asset

Current Asset Comparative Analysis

  Current Asset 
      Merrimack Pharmaceuticals Comparables 
Merrimack Pharmaceuticals is currently under evaluation in current asset category among related companies. Current Asset is all of company's assets that can be used to pay off current liabilities within current fiscal period or over next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Please see also Merrimack Pharmaceuticals Hype Analysis, Merrimack Pharmaceuticals Correlation and Merrimack Pharmaceuticals Performance. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Search macroaxis.com